title: Ceftriaxone and cefotaxime use in Victorian hospitals.
abstract: OBJECTIVE
  To determine patterns of use of ceftriaxone and cefotaxime (CEFX) in Victorian hospitals and to identify areas for improvement.
  
  
  METHODS
  A concurrent, observational evaluation of CEFX use in patients commencing a course of these drugs between 8 and 14 September, 1999, in 51 Victorian hospitals.
  
  
  METHODS
  Proportion of patients treated with CEFX; indications; duration of use; concordance with recommendations of national antibiotic guidelines (Therapeutic guidelines: antibiotic, 10th edition [AG10]).
  
  
  RESULTS
  671 patients were treated with CEFX. The overall rate of use was 43 patients per 1000 inpatient separations. Treatment of respiratory tract infection accounted for 352 patients (52%) and surgical prophylaxis for 99 patients (15%). Treatment of skin/soft tissue, urinary tract and gastrointestinal tract infections accounted for about 7% of patients each. The median duration of CEFX courses was 3.0 days. The overall rate of concordance with indications recommended in AG10 was 27%. The rate of concordance for empirical treatment of respiratory tract infection was 24%. Of the 195 patients treated empirically with CEFX for community-acquired respiratory tract infection and assessed as non-concordant, 64% did not have radiological evidence of pneumonia, and a further 30% did not fulfill the criteria for severe pneumonia. All courses given for surgical prophylaxis were non-concordant.
  
  
  CONCLUSIONS
  CEFX is widely used in Victorian hospitals, mostly to treat lower respiratory tract infection and in surgical prophylaxis of infection. The rate of concordance with AG10 is low. Potential areas for intervention include empirical treatment of respiratory tract infection and use in surgical prophylaxis.
authors.affiliation: Department of Clinical Pharmacology and Therapeutics, The Royal Melbourne Hospital, VIC 3050, Australia. Marion.Robertson@mh.org.au
authors.forename: Marion B
authors.initials: MB
authors.lastname: Robertson
authors.forename: Tony M
authors.initials: TM
authors.lastname: Korman
authors.forename: Jonathan G A
authors.initials: JG
authors.lastname: Dartnell
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Ioannides-Demos
authors.forename: Sue W
authors.initials: SW
authors.lastname: Kirsa
authors.forename: Julie A V
authors.initials: JA
authors.lastname: Lord
authors.forename: Liliana
authors.initials: L
authors.lastname: Munafo
authors.forename: Graham B
authors.initials: GB
authors.lastname: Byrnes
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy; D017723:Drug Utilization Review; D019983:Guideline Adherence; D006761:Hospitals / Q000706:statistics & numerical data; D006784:Hospitals, Teaching / Q000706:statistics & numerical data; D006801:Humans; D016015:Logistic Models; D017410:Practice Guidelines as Topic; D014739:Victoria
chemical_list: D002511:Cephalosporins; D002443:Ceftriaxone; D002439:Cefotaxime